Abstract
Aging is the major known risk factor for the onset of neurodegenerative diseases such as Alzheimers disease (AD) and Parkinsons disease (PD). Mitochondria play a central role in aging as mitochondrial dysfunction increases with age and produces harmful levels of reactive oxygen species which leads to cellular oxidative stress (free-radical theory of aging). Oxidative stress is highly damaging to cellular macromolecules and is also a major cause of the loss and impairment of neurons in neurodegenerative disorders. A growing body of evidence suggests that modulation of sirtuin activity and restricting calorie intake has a strong neuroprotective effect. SIRT1 induction by the use of pharmacological activators or by calorie restriction (CR) diet regimen has been shown to protect against neuronal loss and impairment in the cellular and animal models of AD and PD. Here, we review the current knowledge and recent data related to the role of sirtuins and CR in neurodegeneration and discuss the potential underlying signaling pathways of neuroprotection that might serve as attractive targets for the future therapeutic intervention of these age-related neurodegenerative diseases.
Keywords: Sirtuin, calorie restriction, resveratrol, neuroprotection, SIRT1, SIRT2, AD, PD, neurons, neurogenesis
Current Pharmaceutical Design
Title: Role of Sirtuins and Calorie Restriction in Neuroprotection: Implications in Alzheimers and Parkinsons Diseases
Volume: 17 Issue: 31
Author(s): Sarika Srivastava and Marcia C. Haigis
Affiliation:
Keywords: Sirtuin, calorie restriction, resveratrol, neuroprotection, SIRT1, SIRT2, AD, PD, neurons, neurogenesis
Abstract: Aging is the major known risk factor for the onset of neurodegenerative diseases such as Alzheimers disease (AD) and Parkinsons disease (PD). Mitochondria play a central role in aging as mitochondrial dysfunction increases with age and produces harmful levels of reactive oxygen species which leads to cellular oxidative stress (free-radical theory of aging). Oxidative stress is highly damaging to cellular macromolecules and is also a major cause of the loss and impairment of neurons in neurodegenerative disorders. A growing body of evidence suggests that modulation of sirtuin activity and restricting calorie intake has a strong neuroprotective effect. SIRT1 induction by the use of pharmacological activators or by calorie restriction (CR) diet regimen has been shown to protect against neuronal loss and impairment in the cellular and animal models of AD and PD. Here, we review the current knowledge and recent data related to the role of sirtuins and CR in neurodegeneration and discuss the potential underlying signaling pathways of neuroprotection that might serve as attractive targets for the future therapeutic intervention of these age-related neurodegenerative diseases.
Export Options
About this article
Cite this article as:
Srivastava Sarika and C. Haigis Marcia, Role of Sirtuins and Calorie Restriction in Neuroprotection: Implications in Alzheimers and Parkinsons Diseases, Current Pharmaceutical Design 2011; 17 (31) . https://dx.doi.org/10.2174/138161211798072526
DOI https://dx.doi.org/10.2174/138161211798072526 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Advances in the Molecular Pathogenesis of Inflammatory Bowel Disease.
This thematic issue will emphasize the recent breakthroughs in the mechanisms of Inflammatory bowel disease (IBD) pathogenesis and devotes some understanding of both Crohn’s and ulcerative colitis. It is expected to include studies about cellular and genetic aspects, which help to precipitate the disease, and the immune system-gut microbiome relations ...read more
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Synthesis and Biological Evaluation of 2-Amino-1-phenyl-benzimidazole
Derivatives as BACE1 Inhibitors
Letters in Drug Design & Discovery Essential Fatty Acids - A Review
Current Pharmaceutical Biotechnology The Role of Brain Cholesterol and its Oxidized Products in Alzheimer's Disease
Current Alzheimer Research Choline Alphoscerate (Alpha-Glyceryl-Phosphoryl-Choline) An Old Choline- containing Phospholipid with a Still Interesting Profile As Cognition Enhancing Agent
Current Alzheimer Research Targeted Delivery of Short Interfering RNAs - Strategies for In Vivo Delivery
Recent Patents on Anti-Cancer Drug Discovery Nasal Neuro EPO Could be a Reliable Choice for Neuroprotective Stroke Treatment
Central Nervous System Agents in Medicinal Chemistry Heme Oxygenase-1 as a Therapeutic Target in Neurodegenerative Diseases and Brain Infections
Current Pharmaceutical Design The Association of MME microRNA Binding Site Polymorphism with the Risk of Late Onset Alzheimer’s Disease in Northern Han Chinese
Current Neurovascular Research Melatonin as Potential Targets for Delaying Ovarian Aging
Current Drug Targets Plasma Proteins Interaction with Curcumin Nanoparticles: Implications in Cancer Therapeutics
Current Drug Metabolism Statistical Voxel-Based Methods and [18F]FDG PET Brain Imaging: Frontiers for the Diagnosis of AD
Current Alzheimer Research Potential Gene Therapy Towards Treating Neurodegenerative Disea ses Employing Polymeric Nanosystems
Current Gene Therapy Structure-Based Drug Design, Molecular Dynamics and ADME/Tox to Investigate Protein Kinase Anti-Cancer Agents
Current Bioactive Compounds Can Trehalose Prevent Neurodegeneration? Insights from Experimental Studies
Current Drug Targets Endothelial Extracellular Vesicles Produced by Senescent Cells: Pathophysiological Role in the Cardiovascular Disease Associated with all Types of Diabetes Mellitus
Current Vascular Pharmacology A Review of Biomarkers in Mood and Psychotic Disorders: A Dissection of Clinical vs. Preclinical Correlates
Current Neuropharmacology Effects of Transition Metals in the Conversion Mechanism of Prion Protein and in the Pathogenesis of Prion Diseases
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Synthesis and in vitro Antitumor Effect of New Vindoline Derivatives Coupled with Triphenylphosphine
Current Organic Chemistry Pathophysiology of Neurodegeneration in Familial Amyotrophic Lateral Sclerosis
Current Molecular Medicine Phytocannabinoids: General Aspects and Pharmacological Potential in Neurodegenerative Diseases
Current Neuropharmacology